Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Osimertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutation

NCT03414814 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT03414814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03414814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Osimertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutation
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 4, 2018
Completion date
August 3, 2021
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic nsclc